Clinical trials: Oral Anticoagulation
Coronary Artery Disease, Bleeding
Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures
Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction
- Trial name
- DOAC-NOSTOP (NCT05292846)
- Testing
- Direct-acting oral anticoagulation
- Where
- 4 sites in Italy, Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitario La Fe
Cerebral Vein Thrombosis
Rivaroxaban vs. Warfarin in CVT Treatment
Cerebral venous thrombosis (CVT) is an uncommon venous-type of stroke tends to affect younger patients with somewhat different risk factors and much better outcome compared to arterial strokes.
- Trial name
- RWCVT (NCT04569279)
- Testing
- Rivaroxaban, Warfarin
- Where
- Syria
- Volunteers
- 71 people
- Sponsor
- Damascus University
Warfarin
Patient Self Testing of Warfarin Therapy
To test the hypothesis that home international normalised ratio (INR) monitoring with supervised patient self-testing (PST)can provide comparable or superior time in therapeutic range (TTR) to that provided by traditional…
- Trial name
- NCT00594828
- Testing
- CoaguChek (Patient self testing), Anticoagulation Management Service (AMS)
- Where
- Ireland
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- University College Cork
Pediatric Venous Thromboembolism
Rivaroxaban in Pediatric Patients With DVT
Prospective interventional randomized controlled trial to assess safety and efficacy of rivaroxaban in pediatric patients with acute deep venous thrombosis.
- Trial name
- NCT07618988
- Testing
- Rivaroxaban, Enoxaparin, Heparin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Atrial Fibrillation
Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)
The aim of FINACAF study is to evaluate the incidence and risk of stroke, systemic thromboembolic events, myocardial infarction, major bleeding events, and mortality in relation to different attitudes regarding stroke prevention…
- Trial name
- FinACAF (NCT04645537)
- Volunteers
- 400,000 people
- Sponsor
- Helsinki University Central Hospital
Atrial Fibrillation, Embolism
Oral Anticoagulation and Self-management
An intervention program targeting patients and caregivers based on education about their condition and training in the use of portable coagulomenter to self monitor and training on the treatment adjustment to self manage, can be…
- Trial name
- NCT01878539
- Testing
- coagulometer, training programme
- Where
- Spain
- Volunteers
- 333 people
- Sponsor
- Osakidetza
Bleeding as Complication to Anticoagulation Therapy
Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants
Serious adverse events in patients treated with new oral anticoagulants are underreported.
- Trial name
- NCT02107651
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Hvidovre University Hospital
Maternal Complications After Oral Anticoagulation When Initiated Early and Late After Caesarean Section Done for Patients With Mechanical Heart Valve Prosthesis
Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis
A randomized cohort study applied to patients with mechanical heart valve prosthesis who will be delivered by caesarean section at or after 28 weeks of gestation .
- Trial name
- NCT04855110
- Testing
- Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant), Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)
- Where
- Egypt
- Volunteers
- 114 people
- Sponsor
- Cairo University
Anticoagulants; Increased
Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis
Direct Oral Anticoagulants INTRODUCTION: DOAC's looks like an attractive alternative to VKA because they offer important advantages beyond their easiness of administration, like less interactions and no need of laboratory…
- Trial name
- NCT05705076
- Testing
- catheter induced thromboprophylaxis
- Volunteers
- 1,100 people
- Sponsor
- Mansoura University
Acute Coronary Syndrome, Atrial Fibrillation
Ongoing WARfarin and Coronary STENTing
Patients on warfarin treatment pose particular problems when undergoing percutaneous coronary intervention with stent implantation (PCI-S), because of the poor definition of the optimal antithrombotic strategies to be adopted…
- Trial name
- WAR-STENT (NCT00722319)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- War-Stent Investigators
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
Atrial Fibrillation, Oral Anticoagulation
Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting
Treatment of patients suffering from atrial fibrillation pose problems when percutaneous coronary intervention with stent implantation (PCI-S) is performed.
- Conditions
- Atrial Fibrillation, Oral Anticoagulation, Percutaneous Coronary Intervention
- Trial name
- AFCAS (NCT00596570)
- Testing
- PCI
- Where
- Finland
- Volunteers
- 996 people
- Sponsor
- University of Turku
Oral Hemorrhage
Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients
Patients using anticoagulants present an increased risk of bleeding when subjected to oral surgery. Suspending or reducing the oral anticoagulant dose to perform invasive procedures, may result in thromboembolic events, putting…
- Trial name
- NCT02238288
- Testing
- Aminocaproic acid, Routine dental care, lidocaine and epinephrine
- Where
- Brazil
- Volunteers
- 154 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Atrial Fibrillation
Non-vitamin K Oral Anticoagulants in Cardioversion
Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF).
- Trial name
- FinCV3 (NCT02911545)
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital